Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052358 | 0.90 | MTNR1A (0.35) | SPRNQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL1050658 | 0.80 | MTNR1A (0.35) | SPRNQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL1050660 | 0.76 | MTNR1A (0.35) | SPRNQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL1049805 | 0.72 | NQO2 (0.33) | SPRNQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL78428 | 0.67 | ADRB2 (0.46) | SPRNQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL1049807 | 0.67 | HTR1D (0.35) | NQO2MTNR1AMTNR1BKDM4EHPGD | |
| SCHEMBL1051998 | 0.62 | SPR (0.38) | SPRNQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL15599844 | 0.61 | REN (0.69) | — | |
| SCHEMBL1051996 | 0.61 | KDM4E (0.36) | SPRNQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL91361 | 0.60 | ADRB2 (0.49) | SPRNQO2MTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | SPR 107/4885NQO2 196/4885MTNR1A 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.